Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Castleman's disease Stories

2013-12-08 08:22:23

Siltuximab regulatory filing granted priority review by the United States Food and Drug Administration RARITAN, N.J., Dec. 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care (BSC), exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in...

2013-09-03 08:27:55

RARITAN, N.J., Sept. 3, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") announced the simultaneous submissions of a Biologic License Application (BLA) to the United States Food and Drug Administration (U.S. FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for siltuximab for the treatment of patients with multicentric Castleman disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative. MCD is a...

2009-06-29 17:00:07

Scientists know that some cancers are triggered by viruses, which take over cellular systems and cause uncontrolled cell growth. Doctors "“ and patients who get shingles late in life "“ have also known for many years that some viruses, particularly the herpes virus, can lie dormant in a person's cells for long periods of time and then reactivate, causing disease. These viruses also cause significant disease in immunosuppressed people and those living with HIV/AIDS.A recent study...